Healthcare Profesionals
Tuberculosis
T-SPOT®.TB Overview
Economic Impact
Regulatory Information
Frequently Asked Questions
Healthcare Profesionals
Patients
About Tuberculosis
Diagnosing Tuberculosis
Why Request T-SPOT®.TB?
TB Vaccination and Treatment
Frequently Asked Questions
Patients
Media Members
Media Requests
Consumers

The World Health Organization (WHO) estimates that more than one third of the world’s population is infected with Mycobacterium tuberculosis.

Toggle this branch of the sitemapOxford Immunotec - North AmericaToggle this branch of the sitemapAboutT-SPOT® TechnologyValuesExecutive TeamBoard of DirectorsInvestorsProduct OverviewToggle this branch of the sitemapNews and MeetingsPress ReleasesMeetingsToggle this branch of the sitemapResourcesFAQ - Healthcare ProfessionalsFAQ - PatientsTechnical DocumentsNew CDC GuidelinesToggle this branch of the sitemapCareersValuesEmployment OpportunitiesApply OnlineToggle this branch of the sitemapContactDirectionsToggle this branch of the sitemapHealthcareTuberculosis T-SPOT®.TB OverviewEconomic ImpactRegulatory InformationFrequently Asked QuestionsToggle this branch of the sitemapMediaMedia RequestsToggle this branch of the sitemapPatientsAbout TuberculosisDiagnosing TuberculosisWhy Request T-SPOT®.TB?TB Vaccination and TreatmentFrequently Asked QuestionsToggle this branch of the sitemapRecent NewsResults confirm T-SPOT®.TB is not affected by low CD4 count HIV infected subjectsResults demonstrate ability of T-SPOT®.TB to monitor declining responseT-SPOT. TB Gains FDA Premarket ApprovalSign UpEmail SuccessEmail FailureSend to a FriendTerms of Use Privacy PolicyNA Search Results
Bookmark and Share
Get Email Updates
  • About
  • Product Overview
  • News and Meetings
  • Resources
  • Careers
  • Contact
  • Site Map
  • Terms of Use
  • Privacy Policy



T-SPOT®.TB and the Oxford Immunotec logo are trademarks of Oxford Immunotec | © 2010 Oxford Immunotec